培西达替尼（Pexidartinib，商品名：Turalio）是一种激酶抑制剂，主要用于治疗无法通过手术改善且伴有严重发病率或功能受限的症状性腱鞘巨细胞瘤（TGCT）成人患者。

The FDA has approved Ono’s CSF1R inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumours (TGCT) that are not suitable for surgical resection. It will compete ...

More information: Jaroslaw Dulski et al, Global Presence and Penetrance of CSF1R -Related Disorder, Neurology Genetics (2024) ...

Among the 7MM, the United States had the highest prevalence of tenosynovial giant cell tumor, accounting for approximately 45 ...